Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2187-2190

  Haas, David W ^a   Severe, Patrice ^b   Juste, Marc Antoine Jean ^b   Pape, Jean William ^b,c   Fitzgerald, Daniel W ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AIDS; Antiretroviral therapy; HIV; Pharmacogenomics

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; VIRUS RNA; ABCB1 PROTEIN, HUMAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP2A6 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 2B6 INDUCER; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAITI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIROLOGIC RESPONSE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENETIC ASSOCIATION STUDY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; SECONDARY METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP2B6 INDUCERS; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC ASSOCIATION STUDIES; HAITI; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SECONDARY METABOLISM; TREATMENT OUTCOME;

EID: 84904561614     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku088     Document Type: Article

References (10)

1. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
2. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genom 2005; 15: 1-5.
3. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61: 914-8.
4. Ribaudo HJ, Liu H, Schwab M et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202: 717-22.
5. Holzinger ER, Grady B, Ritchie MD et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genom 2012; 22: 858-67.
6. Lubomirov R, Colombo S, di Iulio J et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203: 246-57.
7. Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-65.
8. WHO. The Strategic Use of Antiretrovirals to Help End the HIV Epidemic. http://apps.who.int/iris/bitstream/10665/75184/1/9789241503921_eng. pdf (17 February 2014, date last accessed).
9. Bertrand J, Chou M, Richardson DM et al. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genom 2012; 22: 868-76.
10. Puls R, Group tES. A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial. In: Abstracts of the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, 2013. Abstract WELBB01.